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The effects of GSK2487213A (213A) on RyR1 function was assessed via skeletal muscle heavy 
sarcoplasmic reticulum (HSR) [3H]ryanodine binding. 213A did not affect HSR ryanodine binding 
when Ca2+ was the sole RyR1 regulator. Stripping HSR of FKBP12.0, via treatment with FK506, 
increased Ca2+-activated ryanodine binding. Exogenous FKBP12.0 alone or in combination with 213A 
and or reducing agents failed to reverse the effects prior exposure to FK506. Including FK506 in the 
HSR [3H]ryanodine binding buffer dose-dependently increased ryanodine binding. 213A did not alter 
the FK506 dose response. Treating HSR with the nitric oxide donor, NOR-3, did not substantially 
reduce the FKBP12.0 content of the HSR. Prior exposure to NOR-3 enhanced Ca2+ stimulated HSR 
ryanodine binding. 213A reversed the NOR-3 activation of RyR1. These results suggest that 213A 
reverses nitrosylation-induced activation of RyR1 and the inhibition does not occur via stabilizing the 
interaction between RyR1 and FKBP12.0. 
 
Introduction 
Ryanodine receptors (RyR) are endo/sarcoplamic reticulum (SR) resident Ca2+ selective channels 
that form the efflux pathway for the release of Ca2+ from the SR to initiate muscle contraction. Isoform 
1 (RyR1) is the predominate form in skeletal muscle, RyR2 is the predominate form in the heart while 
RyR3 has a widespread distribution. The channels are regulated by numerous endogenous effectors 
including ions primarily Ca2+ and Mg2+, metabolites such as the adenine nucleotides and accessory 
proteins including calmodulin and the FK506-binding proteins (FKBP). The sensitivity of the channel 
to these regulators can be modified by post-translational modifications such as phosphorylation and 
oxidation/reduction. 
FKBPs are a family of cis-trans prolyl isomerases. RyR2 binds the 12.6 kD FKBP isoform (FKBP12.6; 
aka FKBP1B and calstabin 2) while RyR1 binds FKBP12.6 and the 12 kD isoform (FKBP12.0; aka 
FKBP1A and calstabin 1) with similar affinities [15]. FKBPs are receptors for the immunosuppressant 
drugs FK506 and rapamycin. Incubation of RyRs with either drug can remove FKBP from the 
channels.  The functional effects of FKBP12.0 association with RyR1 have been suggested to include 
coordinating gating between RyR1 channel monomers to stabilize the full conductance state [1], 
coordinating coupled gating between neighboring channels [12] and coupling RyR1 with the 
transverse-tubule voltage sensor [10]. 
The loss of FKBP12.0/12.6 from RyR1/2 has been implicated in a number of pathologies including 
skeletal [16] and cardiac dysfunction [13] in heart failure, catecholaminergic polymorphic tachacardia 
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[18], seizures [11], muscular dystrophy [5] and skeletal muscle fatigue [6]. Chronic administration of 
S107, a drug designed to stabilize RyR/FKBP interaction has been reported it improve skeletal 
muscle function in models of skeletal muscle fatigue [6] and muscular dystrophy [5]. RyR1 channels 
from drug treated individuals exhibited reduced S-nitrosylation and increased FKBP12.0 binding 
compared to channels from non-drug treated individuals. Functionally, S107 treatment reduced the 
fatigue-induced increase in RyR1 channel activity. Although these studies show that chronic 
administration S107 mitigated some of the biochemical channel modifications and may have modified 
RyR1 function, the target of the drug remains to be determined. Thus, the goals of this project were to 
determine whether GSK2487213A, referred to as 213A for the remainder of this report, has direct 
affect on RyR1 function and whether it increases RyR1 affinity for FKBP12.0. 
  
Methods 
Materials. Pigs were obtained from Clemson University or Valley Brook Farms (Madison, GA). 
[3H]Ryanodine was purchased from PerkinElmer Life Sciences. Unlabeled ryanodine and (±)-(E)-
Ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexene amide (NOR-3) were obtained from  Calbiochem. 
Tacrolimus (FK506) was purchased from Sigma-Aldrich. FKBP12.0 was purchased from Sigma-
Aldrich or provided by Glaxo-Smith Kline (GSK).  
Isolation of heavy sarcoplasmic reticulum vesicles. Skeletal muscle heavy SR vesicles (HSR) were 
prepared from porcine longissimus dorsi muscle [14]. Muscle (25g/100 mL) was homogenized in a 
Waring Blender (75% of full speed 2X30 sec with 30 sec rest) in ice-cold 0.1 M NaCl, 5 mM Tris 
maleate buffer, pH 6.8, and centrifuged for 30 min at 2,600g and 4oC . The supernatant was filtered 
through four layers of cheesecloth and centrifuged for 30 min at 15,000g and 4oC. Pelleted 
membranes were extracted in 1.1 M KCl, 5 mM Tris, pH 6.8, on ice for 60 min., centrifuged at 
130,000g for 45 min at 4oC, and then resuspended in 0.3 M sucrose, 0.4 M KCl, 5 mM Tris, pH 6.8, 
buffer. SR was then centrifuged through a discontinuous sucrose gradient (22, 36, and 45% sucrose) 
at 130,000g for 16 hours at 4oC, and the heavy SR fraction was collected from the 36 and 45% 
sucrose interface. HSR vesicles were resuspended in a minimal volume (1-2 ml) of 0.3 M sucrose, 
0.1 M KCl, 5 mM Tris, pH 6.8, frozen in liquid nitrogen, and stored at −80°C until use. All buffers 
contained a protease inhibitor mixture (1.0 µg/ml aprotinin, 1.0 µg/ml leupeptin, 1.0 µg/ml pepstatin, 
0.2 mM benzamidine, and 0.2 mM phenylmethylsulfonyl fluoride).  
Treatment of HSR with FK506. FK506 was dissolved at 10 mM in 100% ethanol and stored at -20o 
until use .The protocol for removal of FKBP12 from HSR was based on work previously described by 
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Ahern et al [1]. HSR (2 mg/ml) was incubated for 15 minutes at 37o C in a buffer composed of 20 mM  
imidazole pH 7.4, 300 mM sucrose, the protease inhibitor mixture described in the previous section 
with 10 µM FK506 (FK506 treated) or 0.1% ethanol (control treated). SR was collected by 
centrifugation for 15 minutes at 4o C at 109,000 g (40,000 rpm ) in a Beckman 70.1Ti. The pellet was 
resuspended in 300 mM sucrose buffer without FK506 and recentrifuged at 109,000 g. The washed 
pellet was resuspended in a minimal volume of 300 mM sucrose buffer without FK506, frozen in liquid 
N2, and stored at -80o C until use.  
Treatment of HSR with NOR-3. NOR-3 was disolved at 45 mM in 100% dimethyl sulfoxide (DMSO) 
and stored at -20o C until use. Heavy SR (1 mg/ml) was incubated for 30 minutes at 25o C in buffer 
consisting of 150 mM KCl, 20 MOPS pH 7.0, 1 mM sodium EGTA, 0.93 mM calcium chloride (10 µM 
ionized Ca2+) with 0.2 mM NOR-3 (NOR-3 treated) or 0.44% DMSO (control treated). SR was 
collected by centrifugation for 15 minutes at 4o C at 109,000 g (40,000 rpm ) in a Beckman 70.1Ti. 
The pellet was resuspended in 6 ml of sucrose buffer composed of 300 mM sucrose, 20 mM PIPES 
pH 7.0, the protease inhibitor mixture and centrifuged as again at 109,000 g. The pellet was 
resuspended in a minimal volume of 300 mM sucrose buffer, frozen in liquid N2 and stored at -80oC 
until use. 
GSK2487213A handling and storage. 213A was stored protected from the light in a desiccator at 
room temperature (21-23o C). Working solutions were made from an aqueous 10 mM stock solution. 
The stock solution was stored frozen at -20o C for no more than three days and thawed only once.   
HSR [3H]ryanodine binding. [3H]Ryanodine selectively binds to the open RyR and therefore provides 
a useful indicator of channel activity [17]. HSR vesicles (0.2 mg/ml) were incubated at 37°C for 90 min 
in medium containing 150 mM KCl, 10 mM PIPES, pH 7.0, 100 nM [3H]ryanodine, and a Ca-EGTA 
buffer set to give the desired free Ca2+ concentration [8]. Estimates of maximal [3H]ryanodine binding 
capacity of each SR vesicle preparation were determined in medium that in addition contained 500 
mm KCl, 5 mM ATP, and 100 μM Ca2+. Nonspecific binding was measured in the presence of 20 μM 
nonradioactive ryanodine and 0.01 μM Ca2+. [3H]Ryanodine binding is expressed as a percent of 
maximal [3H]ryanodine binding. Removal of FKBP12.0 from RyR1 appears to increase the rate of 
[3H]ryanodine binding, thus to increase the probability of detecting effects of FKBP12.0 on RyR1, the 
rate of SR vesicle [3H]ryanodine binding was slowed by incubation at room temperature (21-23oC) for 
16 hrs. Binding media for the room temperature assays contained 150 mM KCl, 20 mM PIPES pH 
7.0, 1.0 µg/ml aprotinin, 0.1 µg/ml leupeptin, 0.1 mg/ml bovine serum albumin and 20 nM 
[3H]ryanodine.  In some experiments, described in the results section, SR was incubated with the 
reducing agent dithiothreitol (DTT) prior to addition to the assay buffer. Further, in some of these 
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experiments reduced glutathione (GSH) was included in the binding buffer. Estimates of maximal 
[3H]ryanodine binding capacity of each SR vesicle preparation were determined in medium that in 
addition contained 500 mm KCl, 5 mM ATP, and 100 μMCa2+. Nonspecific binding was measured in 
the presence of 20 μM nonradioactive ryanodine, 10 mM MgCl2 and 0.01 μM Ca2+. SR vesicles were 
then collected by filtration on Whatman GF/B filters and washed with 8 ml ice-cold 100 mM KCl.  After 
6 hrs incubation in scintillation fluid, radioactivity retained by the filters was determined by liquid 
scintillation counting using a Beckman LS-5000 scintillation counter. 
Electrophoresis and Western Blotting. Forty micrograms of SR protein was denatured for 10 min at 
95o C in reducing sample buffer (12.5% v/v glycerol, 5% w/v SDS, 0.25% w/v bromophenol blue, 
2.5% (v/v) β-mercaptoethanol, 0.25 M Tris-HCl, pH 6.8) and separated by electrophoresis on a 5-20% 
sodium dodecyl sulfate polyacrylamined gel at 175 V using the BioRad Mini-Protean II system. 
Proteins were either visualized by staining with GelCode Blue (ThermoScientific, Rockford, IL) a 
coomassie based gel stain or transferred to polyvinylidene fluoride membranes using a buffer 
consisting of 192 mM glycine, 20% methanol and 25 mM Tris pH 8.3 at 30 V with a 0.1 A current limit 
for 18 hrs at 4o C. Voltage was then increased to 200 V for 1 hr with a current limit of 0.5 A. After 
transfer, membranes were cut at approximately the 75kD molecular weight marker. The membrane 
containing proteins >75kD was probed for RyR1. The membrane section containing proteins <75 kD 
was probed for FKBP12.0. Membrane were  blocked for 60 min in phosphate-buffered saline, 0.1% 
Tween-20 (PBS-T) plus 5% bovine serum albumin (BSA) and washed 3X15 min in PBS-T. 
Membranes were probed overnight at 4o C with either mouse monoclonal anti-RyR antibody (clone 
34C, Iowa Developmental Studies Hybridoma Bank) at a dilution of 1:10,000 in PBS-T and 5% BSA 
or an affinity purified goat anti-FKBP12.0/12.6 antibody (R & D Systems AF4174) diluted 1:1,000 in 
PBS-T containing 5% BSA, and 0.5 M NaCl. The secondary antibodies is these experiments were a 
horseradish peroxidase conjugated goat anti-mouse IgG secondary antibody (12-249, Millipore) used 
at a 1:100,000 dilution for the RyR and a donkey anti-goat IgG (Santa Cruz sc-2020) also used at 
1:100,000. Antigen-antibody interactions were visualized using enchanced chemiluminence (GE 
Healthcare) and Kodak Biomax film. 
Analysis. The Ca2+ dependence of ryanodine binding was fit with Equation 1, which assumes a high 
affinity Ca2+ binding site, which when bound will activate the RyR and a lower affinity Ca2+ binding site 





where B is the [3H]ryanodine bound, BO is the 
maximal Ca2+ stimulated [3H]ryanodine binding, 
EC50 and IC50 are the half-activating and half-
inhibiting Ca2+ concentrations, respectively, and 
yo is the baseline [3H]ryanodine binding. The 
FK506 concentration dependence of HSR vesicle 
[3H]ryanodine binding were fit with a four-parameter Hill 
equation. Comparisons between two groups were made using 
Student t-test. Multiple comparisons were by one-way analysis 
of variance with a Holm-Sidak post-hoc test. Statistical 
analysis was performed using SigmaStat 3.0 (Systat Software, 
Point Richmond, CA). Data are reported as the mean±SEM. 
The level of significance was p<0.05. 
 
Results 
 Initial experiments were designed to determine 
whether 213A affected RyR1 activity with Ca2+ as 
the sole regulator. The 213A concentration 
dependence of skeletal muscle HSR vesicle 
[3H]ryanodine binding were performed under our 
standard conditions (37o C for 90 minutes) in 
media containing either 1 or 30 μM free Ca2+. 
Figure 1 shows that increasing buffer Ca2+ increased SR vesicle ryanodine binding, however, 213A, 
up to 100 μM, did not significantly alter binding. A control experiment shown in 1B demonstrates the 
well-characterized caffeine-induced increase in channel activation and the ruthenium red inhibition of 
the channel. 
Table 1. Effects of 213A on the Ca2+ of HSR [3H]ryanodine 
binding. 
 Control +1 μM 231A p 
Extent of 
Activation      
(% BO) 
61.0±2.4 56.8±2.6 0.258 
EC50 (μM) 0.81±0.16 0.83±0.18 0.935 
C50 (μM) 528±102 433±96 0.510 
y0            
(% maximal 
binding) 
0.09±1.6 0.7±1.6 0.972 
Calcium (μM)



























Figure 2. Ca2+-dependence of SR vesicle 
[3H]ryanodine binding performed as 
described in the methods in media containing 
the indicated concentration of free Ca2+ ±1 
μM GSK2487231A, n=7. Inset is a control 
experiment demonstrating the well 
characterized caffeine activation (■) and 
ruthenium red (●) inhibition of SR vesicle 
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Figure 1. GSK2487213A concentration dependence of 
[3H]ryanodine binding as described in the methods in media 
containing either 1 or 30 μM free Ca2+ and the indicated 
concentration of 123A, n=4 (A). A control experiment 
demonstrating the well characterized caffeine activation and 
ruthenium red inhibition of SR vesicle ryanodine binding (B). 
 The effects of 213A on RyR1 regulation were further investigated by examining the Ca2+-
dependence of HSR [3H]ryanodine binding. Including 1 µM 213A in the binding media causes a small 
but non-significant reduction in the maximal Ca2+-activated ryanodine binding (Figure 2, Table 1). 
Further, addition of 213A to the assay had no effect on the Ca2+ 
concentration required to half-activate (EC50) or half- 
 inhibit (IC50) the channel. In contrast, 5 mM caffeine increased while 
100 µM ruthenium red reduced SR vesicle ryanodine binding (Figure 
2, inset). Together these experiments indicate 213A has no 
significant effects on Ca2+ regulation of RyR1. 
 Next, the effects of removing FKBP12.0 from RyR1 on 
channel regulation were examined. As is clear from the 
representative Western blot shown in Figure 3, treating HSR 
with 10 µM FK-506 for 15 minutes at 37o C following by 
washing and centrifugation removed FKBP12.0 from the 
treated SR. SR treated in an identical manner without FK506 
retained FKBP12.0.  
To determine the functional effects of FKBP12.0 removal on 
RyR1 function, the Ca2+-dependence of ryanodine binding by 
control and FK506 treated SR vesicles was determined. Initial 
studies, performed at 37oC for 90 minutes, failed to 
demonstrate an effect of FKBP12.0 removal on the Ca2+-
dependence of ryanodine binding (Figure 4). Slowing the rate of 
ryanodine binding by lowering the incubation temperature to 
room temperature (21-23oC; for 16 hrs) revealed a significant 
increase in the maximal Ca2+-stimulated HSR ryanodine binding 
(Figure 5, Table 2) with no change in the Ca2+ EC50 or IC50.  
 Activation of RyR1 by removal of endogenous FKBP12.0 from 
RyR1 should be reversible by the addition of exogenous 
FKBP12.0. Thus, addition of exogenous 
FKBP12.0 to the binding media should 
reduce ryanodine binding by FK506-
treated HSR. Further, if 213A increases 
RyR1 affinity for FKBP12.0, this inhibition 
should occur at lower FKBP12.0 concentrations. Thus, experiments were undertaken to examine the 
effects 213A on the FKBP12.0 concentration dependence of FK506-treated HSR vesicle ryanodine 
Table 2. Effects of FK506 treatment on the Ca2+ dependence of SR vesicle 
[3H]ryanodine binding. 
 Control Treated FK506 Treated p 
Extent of Activation 
(% BO) 
24.1±1.9 32.5±2.0 0.012 
EC50 (µM) 1.32±0.32 1.10±0.23 0.59 
IC50 (µM) 83±20 92±19 0.76 
yo (%Bmax) 0.04±0.5 0.5±0.6 0.58 
Calcium (μM)


























Figure 5. Ca2+-dependence of 
[3H]ryanodine binding by FK506 and 
control treated SR vesicles. Binding was 
performed as described in the methods for 
16 hrs at room temperature, n=6.
Calcium (μM)






















Figure 4. Ca2+-dependence of control and 
FK506 treated SR vesicle [3H]ryanodine 
binding. Binding was performed as described 
in the methods for 90 min at 37o C, n=5. 




Figure 3. Western blots of control 
and FK506 treated SR. Treatment 
of SR with 10 µM FK506 for 15 
min at 37o C removes FKBP12.0 
from the SR preps. Successive 
lanes are paired control and 
FK506 treated SR preps.    
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Figure 6. Sigma-Aldrich FKBP12.0 
dependence of [3H]ryanodine binding to 
FK506 treated HSR. Binding was performed 
as described in the methods in buffer 
containing 10  µM Ca2+ ±1 µM 213A, n=3. 
binding.  Surprisingly, FK506-treated HSR ryanodine binding 
was not reduced by the addition of exogenous FKBP12.0, 
either in the absence or in the presence of 1 µM 213A.   
Both RyR1 and FKBP12.0 contain oxidizable cysteine 
residues, 100 in RyR1 and 1 in FKBP12.0. RyR1 FKBP12.0 
binding is reduced under oxidizing conditions. In addition, 
binding of FKBP12.0 to RyR1 appears to protect a sensitive 
RyR1 cysteine residue from oxidative modification [19]. Prior 
to FK506 treatment, RyR1 is bound with FKBP12.0 and is 
unlikely to be oxidized at residues critical for the RyR1-
FKBP12.0 interaction.  However, the channel may be modified 
during the FK506 treatment or alternatively the exogenous 
FKBP12.0 may be modified. In an attempt to reverse any 
oxidative channel modification that may have occurred during 
the FK506 treatment, SR was incubated in 10 mM DTT for 30 
minutes at room temperature prior to use. After addition to the 
binding buffer, HSR solution makes up 10% of the assay 
solution volume, thus the concentration of DTT in the assay 
buffer is 1 mM. Further, 1 mM reduced glutathione (GSH) was 
included in the binding media. As shown in Figure 7, treatment 
with DTT and GSH reduced HSR vesicle ryanodine binding in 
the absence and presence of FKBP12.0.  However, 
FKBP12.0, up to 10 µM did not alter SR vesicle ryanodine 
binding, either in the presence or absence of DTT and GSH.  
A similar experiment was performed with the addition of 1 or 2 
mM GSH to the binding buffer and either incubating HSR with 
or without DTT (Figure 8). In this experiment, there was dose-
dependent inhibition of ryanodine binding by the reducing 
compounds but no effect of FKBP12.0. 
FKBP12.0 (nM)

























Figure 7. GSK FKBP12.0 concentration 
dependence of SR vesicle [3H]ryanodine 
binding. Binding was performed as described 
in the methods in 10 µM Ca2+ for 16 hrs at 
room temperature ± 1 mM GSH. SR was 
either pre-incubated ±10 mM DTT at room 
temperature for 30 minutes, n=3. 
FKBP12 (nM)





















1 mM GSH + DTT
2 mM GSH
2 mM GSH + DTT
 
Figure 8. GSK FKBP12.0 dependence of 
[3H]ryanodine binding to FK506 treated SR. 
Binding was performed for 16 hrs at room 
temperature as described in the methods in 
buffer containing 10 µM Ca2+ and either 1 or 
2 mM GSH. SR was preincubated for ≥30 min 
in the absence or presence of 10 mM DTT. 
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The FKBP12.0 used in the previous experiments was obtained 
from two different sources, Sigma-Aldrich and GSK. The Sigma-
Aldrich FKBP12.0 was shipped in a solution containing 0.5 mM 
DTT and thus is unlikely to have been significantly oxidized. To 
determine whether reduction of GSK FKBP12.0 altered its ability 
to inhibit FK506-treated SR, FKBP12.0 was incubated in 2 mM 
DTT for 30 minutes prior to use in a binding assay.  Reduced 
GSK FKBP12.0 did not inhibit FK506-treated SR vesicle 
ryanodine binding (Figure 9). The results presented in figures 6-
9 suggest that an easily reversible oxidative modification of 
either RyR1 or FKBP12.0 does not underlie the lack of 
FKBP12.0 inhibition of the channel in these preparations.  
FKBP12 (nM)





















Figure 9. FK506-treated SR vesicle 
[3H]ryanodine binding was performed as 
described in the methods at room 
temperature. GSK FKBP12.0 and SR were 
separately incubated in 2 mM DTT for 30 
minutes at room temperature prior to 
addition to assay buffer containing 1 mM 
GSH.  
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As an alternative approach to determine whether 213A stabilizes 
FKBP12.0 binding to RyR1, the FK506 concentration 
dependences of SR vesicle ryanodine binding in media containing 
either no 213A or 1 µM 213A were compared (Figure 10). 
Including 213A in the binding media did not alter either the FK506 
EC50 (No 213A: 0.13±0.05 µM; 213A: 0.13±0.02 µM) or the Hill 
coefficient (No 213A: 1.19±0.47 213A: 1.48±0.34).  
RyR1 nitrosylation has been reported to decrease the affinity of 
the channel for FKBP12.0 [1]. Therefore, we examined the effects NOR-3 on the HSR FKBP12.0 
content and the Ca2+-dependence of HSR ryanodine binding (Figure 11, Table 3).  NOR-3 treatment 
did not substantially reduce the FKBP12 content of our HSR preparations, it did however, enhance 
Ca2+-activated HSR ryanodine binding. Although the Ca2+-dependence of control treated HSR was 
not affected by including 1 µM 213A in the binding buffer, 213A reduced Ca2+-activation of NOR-3 
treated RyR1 such that there was no difference between the Ca2+-dependence of ryanodine binding 
by NOR-3 treated HSR+123A  and control treated HSR. 
FK506 (μM)























1 uM 213A 
No 213A 
Figure 10. FK506 concentration 
dependence of SR vesicle [3H]ryanodine 
binding. Binding was performed as 
described in the methods at room 
temperature ±1µM 213A. 
 
DISCUSSION 
The primary goal of this project was to determine whether 213A affects the functional interaction 
between FKBP12.0 and RyR1. RyR1 channel activity was assessed via HSR vesicle [3H]ryanodine 
binding. Ryanodine binding to open RyR channels occurs with high affinity and selectivity and is 
therefore a sensitive indicator of the 
number of open channels. Although 
changes in ryanodine binding are the 
results of regulatory ligand interaction with 
the channel, binding of the putative 
regulator to the RyR is not measured.  
 Initial experiments indicate that 213A, up to 
100 μM did not affect RyR1 channel 
activation at low (3 μM) to moderate (30 
μM) Ca2+. Further, 1 μM 213A did not 
significantly alter ryanodine binding at free 
Ca2+ between 0.01 and 10,000 μM. This is 
in contrast with the recently published 
effects of the related benzothiazepine K201 
(JTV519).  Blayney et al [7] reported that at 
3 μM Ca2+, 0.1 μM K201 significantly 
reduced FKBP12-stripped RyR1 
[3H]ryanodine binding. Binding assays were 
performed under similar 
conditions as used in 
experiments shown figures 
1 and 2 (37o C for 90 
minutes). While 
dephosphorylation or PKA 
phosphorylation of the channel did not alter the Ca2+ dependence of ryanodine binding, the authors 
report that K201 reduced Ca2+ activation of the channels regardless of the phosphorylation status. 
However, the effect on the phosphorylated channels was quite small and of questionable significance. 
Further, the use of paired t-tests on ryanodine binding data is unusual.  Not only does the K201 data 
differ from the current 213A results, it appears to be inconsistent with itself. Figure 5A from that paper 
shows inhibition of ryanodine binding by 1 μM K201 but figure 5D shows no effect of 1 μM K201.  
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Almassy et al [2] examined the effects of K201 on RyR1 channels incorporated into planar lipid 
bilayers. In this work, channels were more fully inhibited by K201; 10 µM K201 reduced RyR1 open 
probability approximately 10% and channels were nearly closed by 100 µM K201. K201 also had the 
Table 3. Effects of NOR-3 and 213A on parameters for fit to Ca2+ dependence curves. 




+ 1 μM 213A 
NOR-3 Treated + 
1 μM 213A 
Extent of Activation (% 
BO ) 
47.4±1.3 53.6±1.7* 45.4±1.6 49.9±1.9 
EC50 (μM) 0.67±0.09 0.59±0.10 0.76±0.13 0.80±0.15 
IC50 (μM) 351±46 456±73 342±57 375±69 
yo (% maximal) 0.6±0.8 0.4±1.2 0.9±1.0 1.0±1.2 
*Significantly different from Control Treated, p<0.05. 
A. 
                       
RyR
NOR-3
+     - +     - +      -
FKBP   
 
B. 
b) Control vs NOR-3











d) Control vs NOR-3+213A




60c) NOR-3 +/- 213A
Calcium (μM)
























Figure 11. Effects of NOR-3 treatment on the Ca2+ dependence of 
ryanodine binding. A) RyR and FKBP western blot analysis of NOR-3 
treated SR. Consecutive lanes are paired control and NOR-3 treated 
SR preparations.  B) Ca2+-dependence of [3H]ryanodine binding to 
control and NOR-3 treated SR vesicles as described in the methods at 
37o C with or without the addition of 1 µM 213A to the binding buffer. 
interesting effect of inducing a channel sub-conductance state at all drug concentration examined. A 
characteristic of FKBP12.0 stripped RyR1 channels is the appearance of multiple sub-conductance 
states [9]. The lack of channel sub-conductance states in the control recordings strongly suggests 
that channels were bound with FKBP12.0. Thus, K201 had direct effects on RyR1 and the inhibition 
was not due to stabilizing the FKBP12.0- RyR1 interaction. 
Removal of FKBP12.0 from our porcine HSR preparations significantly increased ryanodine binding 
at optimal Ca2+ concentrations when binding was performed at room temperature but not when 
binding was performed at 37o C. However, the addition of exogenous FKBP12.0 did not reduce 
ryanodine binding. This is surprising given that recombinant human FKBP12.0 has previously been 
shown to inhibit ryanodine binding by FK506-treated porcine SR under virtually identical conditions 
(150 mM KCl, 20 mM PIPES pH 7.0, BSA and protease inhibitors, 20 nM [3H]ryanodine, 16 hr room 
temperature incubation; Guo et al, 2010 Supplemental Data). The amino acid sequence of the human 
and rabbit  FKBP12.0s used are identical and differ only slightly from the pig FKBP12.0 (see 
sequence comparison below). The one difference major difference in the assay conditions was the 
use of 5 mM GSH in the Guo et al study and only 1-2 mM GSH in the current work.  
 
Human – Pig FKBP12.0 Sequence Comparison
 
Human/Rabbit   MGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGW  60 
                 Pig    MGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFVLGKQEVIRGW  60 
 
Human/Rabbit  EEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE  108 
                 Pig   EEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPNATLVFDVELLKLE  108 
RyR1 contains 100 cysteine residues and FKBP12.0 contains a single cysteine, thus oxidation of 
either protein may have prevented channel inhibition by exogenous FKBP12.0. In general, oxidation 
activates RyR1 while reduction inhibits the channel. Binding of FKBP12.0 by RyR1 is sensitive to 
redox state and the interaction between FKBP12.0 and RyR1 appears to protect an oxidizable 
cysteine residue that is critical for FKBP12.0 binding [19].  It is possible that this critical cysteine 
residue is protected in our HSR preparations while endogenous FKBP12.0 is bound and is oxidized 
during the FK506 treatment. This would explain the channel activation by FK506 and the inability of 
exogenous FKBP12.0 to inhibit the channel. Attempts were made to reverse cysteine oxidation by 
incubating SR with DTT prior to use and by including GSH in the binding assay. The decrease in SR 
ryanodine binding under these conditions indicates these treatments reduced a number of cysteine 
residues. In spite of reduced conditions of the SR and assay buffer, the channel remained insensitive 
inhibition by exogenous FKBP12.0. The FKBP12.0 purchased from Sigma-Aldrich contains DTT and 
is unlikely to be oxidized. GSK FKBP12.0 pretreated with DTT and added to binding buffer containing 
GSH also failed to inhibit FK506-treated HSR.  Channel phosphorylation has been suggested to 
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reduce FKBP12.0 binding to RyR1, however, this possibility is rejected as ATP is not present at any 
point in the experiment. A trivial explanation is the incomplete removal of FK506 from the HSR prior 
to use in the ryanodine binding assay. This is unlikely. Considering the small volume of HSR treated 
(~0.1 ml), the volume of washes (6 ml) and the greater than 10X dilution of the HSR into the 
ryanodine binding buffer the concentration of FK506 in the assay buffer would less than 0.1 nM. 
Thus, the more likely cause of the lack of exogenous FKBP12.0 inhibition is an irreversible 
modification of either the channel or the FKBP. 
As an alternative to the FKBP12.0 add-back experiments, the effects of 213A on the FK506 
concentration dependence of channel activation was investigated. The addition of FK506 to the assay 
buffer increased HSR ryanodine binding in a concentration-dependent manner. The activator 
occurred over approximately a 10-fold range of FK506 concentration. The dependence of ryanodine 
binding on FK506 concentration was not altered by the inclusion of 213A in the binding media 
suggesting 213A does not stabilize the binding of FKBP12.0 to RyR1. 
Aracena et al [3,4] reported that incubation of SR with NOR-3 results in RyR1 S-nitrosylation, 
enhanced Ca2+ activation of the channel and reduced affinity of the channel for FKBP12.0. Thus, we 
investigated the effects of 213A on NOR-3 treated SR ryanodine binding. Although we did not 
quantify RyR1 S-nitrosylation, our NOR-treatment protocol was based on that of Aracena et al [4] and 
likely resulted in channel nitrosylation. While we did not observe a substantial loss of FKBP12.0 from 
our NOR-3 treated SR preparations, we did observe the expected increase in Ca2+-activated 
ryanodine binding. Therefore, the NOR-3 induced channel activation was independent of FKBP12.0 
loss. Interestingly, 213A did not reduce ryanodine binding when RyR1 was activated by Ca2+ alone 
but the drug did reverse NOR-3 activation of the channel. This preliminary finding should be 
confirmed by 213A ryanodine binding dose-response curves and RyR1 S-nitrosylation should be 
verified. Binding results should be replicated using a second methodology such as single channel 
recording. However, these experiments are beyond the scope of the current project. If these results 
are verified the findings would indicate that 213A may not affect RyR1 under basal conditions, but 
may blunt the effects of specific channel activators.  This characteristic of 213A would be beneficial 
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